GlassScriptPhysician profile
Sara Petro
NPI 1396317509
$8,342.17
in general payments reported to CMS, 2019-2025
24 companies · $4,181 in 2025
The $4,181 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $744 · 2023: $1,008 · 2024: $2,155 · 2025: $4,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,137 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.01 |
| Education | $206.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $957.84 | 2023-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $884.07 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $795.10 | 2023-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $742.62 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $714.59 | 2023-2025 | Zoryve |
| Abbvie INC. | $704.31 | 2021-2025 | |
| Amgen INC. | $487.46 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $436.33 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $354.93 | 2022-2025 | |
| Dermavant Sciences, INC. | $289.54 | 2023-2024 | Vtama |
| Almirall LLC | $263.43 | 2021-2025 | Seysara, Klisyri |
| Novartis Pharmaceuticals Corporation | $243.96 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $236.43 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $211.99 | 2023-2025 | Winlevi |
| Organon LLC | $208.99 | 2025 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $195.93 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $155.93 | 2024-2025 | Sotyktu |
| Epi Health, LLC | $126.14 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.53 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Pfizer INC. | $38.61 | 2025 | |
| Botanix Sb INC | $35.62 | 2025 | Sofdra |
| Convatec INC. | $31.82 | 2025 | |
| Leo Pharma INC. | $31.01 | 2024-2025 | Anzupgo, Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Petro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.